This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Patient Compliance With Enteric-Coated Weekly Fluoxetine During Continuation Treatment of Major Depressive Disorder

Erik de Klerk, MD, MSc

Published: January 8, 2001

Article Abstract

Background: A once-weekly enteric-coated formulation of fluoxetine represents a new, effectiveoption for the long-term treatment of clinically diagnosed depression. This study assessed compliancewith the new once-weekly fluoxetine as compared with once-daily fluoxetine treatment. Method: Adult patients from the United Kingdom who had responded to fluoxetine treatment for a current episode ofdepression (DSM-IV criteria) were monitored for compliance with daily and weekly dose administrationof fluoxetine. The study consisted of 2 study phases. Study phase I was a baseline assessment of 20mg of fluoxetine daily dosing for 4 weeks (N = 117). The second phase of the study consisted of randomlyassigning patients to either once-weekly (90 mg/wk) or once-daily (20 mg/day) fluoxetine for 3months (weekly, N = 56; daily, N = 53). Compliance with the dosing regimen was measured using anelectronic Drug Exposure Monitor (eDEM, AARDEX Ltd., Zug, Switzerland). Results: For thosepatients randomly assigned to weekly fluoxetine, compliance was 85.4% during study period I while ontreatment with daily fluoxetine and then 87.5% while on treatment with weekly fluoxetine. This differencewas not significant. For once-daily dosing, however, compliance declined from 87.3% during periodI to 79.4% during period II (p < .001). After adjusting for compliance during study period I, weeklycompliance during study period II was 87.8% and daily compliance was 79.0%, a statistically significantdifference (p = .006). Conclusion: Compliance with once-weekly fluoxetine was better than thatwith once-daily fluoxetine. Compliance decreased over time when patients remained on daily dosing;however, when patients switched from daily dosing to weekly dosing, compliance did not decrease. Theresults of this study allay concerns about inferior compliance with a once-weekly regimen comparedwith the conventional once-daily regimen.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: